Tag Archives: Greg Conko

CEI Podcast for February 16, 2012: Washington’s Prescription Drug Shortage


Have a listen here.

Patients are suffering from a nationwide shortage of more than 260 different prescription drugs, many of them for different types of cancer. Senior Fellow Greg Conko explains why the biggest culprit for the drug shortage is Washington. DEA and FDA regulations make it difficult to ramp up supply, or to change prices to more accurately reflect demand.

No Such Thing as an Average Cancer Patient

My colleague Greg Conko has an excellent piece in today’s Wall Street Journal. Greg doesn’t think it’s right that the FDA is denying terminally ill patients access to potentially life-saving treatments.

The latest case in point is a drug called Avastin. It is approved for treating several types of cancer. But the FDA is moving to revoke its approval for treating breast cancer. This has, understandably, upset many breast cancer patients and their doctors.

The heart of the matter is who shall be in charge of treatment decisions. Should it be patients and doctors? Or should the FDA decide for them?

Greg thinks a decentralized approach is better. Different patients will react to the same drug in different ways. A doctor can see if Avastin works or not for a patient, and they can make the right decision from there. The FDA relies on averages and medians for making its approval decisions, ignoring individuals. The trouble with that is, as Greg points out, there is no such thing as an average cancer patient.

A few weeks ago, I interviewed Greg about Avastin and the FDA here.

CEI Podcast for May 31, 2011: FDA Rescinds Approval of Breast Cancer Drug

 

Have a listen here.

Senior Fellow Greg Conko breaks down the fight over Avastin, a drug used to treat several types of cancer. The FDA is poised to rescind Avastin’s approval for treating breast cancer. It will retain its approval for other cancers. This will make life difficult, and possibly shorter, for some breast cancer patients. Conko believes this battle boils down to one question: who decides which treatments patients can use? Will it be the FDA, or doctors and patients?

CEI Podcast for March 17, 2011: Are Biotech Crops Coming to Kenya?

Have a listen here.

CEI Senior Fellow Greg Conko discusses his recent trip to Kenya where he met with members of Parliament and other officials about the best way to regulate the introduction of genetically modified crops to the country.

CEI Podcast – November 30, 2010: Food Safety, Washington-Style

Have a listen here.

CEI Senior Fellow Greg Conko looks at the major provisions of the food safety bill that the Senate is voting on today. The bill would set in stone ever-evolving best practices. Changes to plant inspection and food recall policies are a mix of ineffectiveness and perverse incentives that could raise food prices. Overall, the FDA is too blunt an instrument to be effective on this sensitive issue.

CEI Podcast – September 23, 2010: The Frankenfish Myth

Have a listen here.

CEI Senior Fellow Greg Conko, author of The Frankenfood Myth, talks about the promise and imagined peril of genetically modified salmon. The controversial creature reaches normal size twice as fast as unmodified salmon.